These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31416579)

  • 21. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
    Yang L; Yang S; Liu Y; Li J; Hu X; Wang Y; Zhang Y; Wang Y
    Thorac Cancer; 2018 Jun; 9(6):693-698. PubMed ID: 29655198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
    Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
    Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
    Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
    De Luca A; Normanno N
    Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor.
    Chen B; Luo J; Gu W; Shen L; Wang H; Zhou S
    Cell Biochem Biophys; 2015 Dec; 73(3):799-804. PubMed ID: 27259328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.
    Jung M; Cho BC; Lee CH; Park HS; Kang YA; Kim SK; Chang J; Kim DJ; Rha SY; Kim JH; Lee JH
    Yonsei Med J; 2012 Nov; 53(6):1128-35. PubMed ID: 23074112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
    Sluga R; VAN DEN Borne BEEM; Roepman P; Peters BJM; Kastelijn EA; Schramel FMNH
    Anticancer Res; 2018 Jan; 38(1):393-400. PubMed ID: 29277800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
    Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced
    Solassol I; Pinguet F; Quantin X
    Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31671561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Hua H; Zeng J; Xing H; He Y; Han L; Zhang N; Yang M
    Life Sci; 2022 May; 296():120408. PubMed ID: 35202641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Robles AI; Faus-Dáder MJ; Calleja-Hernández MÁ
    Mutat Res Rev Mutat Res; 2017; 771():32-58. PubMed ID: 28342452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Zhang N; Li Y; Xie M; Song Y; Liu J; Lei T; Shen Y; Yu J; Yang M
    Biochem Pharmacol; 2020 Feb; 172():113772. PubMed ID: 31866302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.